Paris, 29 May 2018
Summary
Prescrire took part in the informal consultation undertaken by the Pharmacovigilance and Risk Assessment Committee (PRAC, the EMA’s medicines safety body), regarding medication errors due to daily instead of weekly administration of methotrexate in non-oncologic indications, and evaluating the effectiveness of risk minimisation measures intended to prevent such errors. Prescrire urges that several root causes which are within the remit of the European Medicines Agency, such as regulation, packaging, labelling and medication safety awareness, not be overlooked.
©Prescrire 2018
> Download Prescrire's response to the PRAC consultation (pdf, 144 Ko)
| Share |
 |
 |